Factors Associated With Survival in Patients Having Pneumocystis Jirovecii (NCT06173453) | Clinical Trial Compass
UnknownNot Applicable
Factors Associated With Survival in Patients Having Pneumocystis Jirovecii
France300 participantsStarted 2023-01-01
Plain-language summary
Pneumocystis jirovecii is a fungus that can colonize the airways of some patients and be responsible for a disease called pneumocystosis in other patients and mainly in immunocompromised patients.
Pneumocystosis was mainly linked to HIV in the 1990s, but with the advent of new immunosuppressive molecules used in cancers or autoimmune diseases and with the increase in the number of transplants, the epidemiology has changed in recent years.
Studies on P. jirovecii-related mortality are only based on patients with pneumocystosis. As a result, patients who are simply colonized or patients who are sick but not treated are not taken into account in these studies. The investigators therefore wish to study the overall mortality at six weeks and at three months in all patients with a positive sample for P. jirovecii
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria:
* Adult patients with a positive respiratory sample for P. jirovecii cared for in Strasbourg University Hospitals between 01/01/2016 and 31/12/2018. Positive samples are defined as a direct examination finding cysts or trophozoites after staining with May-Grunewald-Giemsa and/or Gomori-Grocott, a positive P. jirovecii PCR on sputum, tracheal aspirates or bronchial fluid -alveolar
* Subject not objecting to the reuse of their data for scientific research purposes.
Exclusion criteria:
\- Subject having expressed its opposition to the reuse of its data for scientific research purposes.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study is looking at factors associated with survival at six weeks and three months after a Pneumocystis jirovecii infection — what does my current situation look like in terms of those timeframes, and are there specific risk factors my doctor has identified that might affect my outlook?
2Since this appears to be an observational study rather than a treatment trial, does participating mean I would just be sharing my medical data, and would it have any effect at all on the actual treatment I receive?
3The recruitment status for this trial is listed as unknown — is this study still actively enrolling patients, and if so, would my case even be eligible to be included?
4Given that this research is focused on survival outcomes, are there particular underlying conditions or immune system factors in my case that research like this has highlighted as especially important to address during my treatment?
5What standard treatments are currently available for Pneumocystis jirovecii infection, and would being part of this observational study in any way influence or change the treatment plan you would recommend for me?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Survival at six weeks and three months after infection